NCT07187674View on ClinicalTrials.gov

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 30, 2025

Primary Completion Date

June 15, 2028

Study Completion Date

December 31, 2028

Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
DRUG

Iparomlimab and tuvonralimab combined with olaparib and paclitaxel

The main objective of this study is to evaluate the tpCR of early high-risk TNBC with HRD positive treated with Iparomlimab and tuvonralimab combined with olaparib and paclitaxel as neoadjuvant therapy

All Listed Sponsors
lead

Harbin Medical University

OTHER